LeonaBio to Complete ELAINE-3 Enrollment in Q4, Hosts April 29 Lasofoxifene Webinar
LeonaBio expects to complete enrollment in its ELAINE-3 Phase 3 study of lasofoxifene in ER+/HER2–, ESR1-mutated metastatic breast cancer in 4Q26, with top-line data slated for 2H27. An April 29 virtual event features experts discussing Phase 2 results: 5.6-month median PFS versus 3.7 months and 56% response rate with abemaciclib.
1. Virtual Event Overview
LeonaBio will host a virtual Key Opinion Leader webinar on April 29 at 12:00 p.m. ET featuring two leading breast cancer physicians and its CEO to discuss lasofoxifene’s potential to transform treatment for ER+/HER2–, ESR1-mutated metastatic breast cancer.
2. ELAINE-3 Trial Timeline
The ongoing ELAINE-3 Phase 3 study of lasofoxifene plus abemaciclib is expected to complete patient enrollment in Q4 2026, with top-line efficacy and safety data projected for release in the second half of 2027.
3. Key Phase 2 Data
Prior Phase 2 trials demonstrated lasofoxifene’s median progression-free survival of 5.6 months versus 3.7 months for fulvestrant, a 13.3% objective response rate versus 2.9% and a 56% response rate when combined with abemaciclib, supporting its advancement.